Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Semaglutide in type 2 diabetes with chronic kidney disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, semaglutide also significantly reduced the rate of eGFR decline (annual slope difference 1•16 mL/min per 1•73 m², 0•86-1•47), MACE (HR 0•82, 0•68-0•98), and all-cause mortality (HR 0•80, 0•67-0•95)”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Treatment with injectable semaglutide 1 mg once weekly reduced the relative risk for the composite primary outcome (ie, ≥50% eGFR decline, eGFR <15 mL/min per 1•73 m², dialysis or transplant, or death due to kidney disease or cardiovascular disease) by 24% compared with placebo (HR 0•76, 0•66-0•88).26”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [26]
In the citing paper
“Moreover, the GLP-1 receptor agonist, semaglutide reduced the risk of a composite kidney end point in a dedicated kidney outcome trial.11”
From The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity (2025) · cites this paper as [11]
In the citing paper
“semaglutide can reduce the progression of chronic kidney disease in patients with and without diabetes and even in those taking SGLT2 inhibitors [12–14].”
From New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? (2025) · cites this paper as [13]
In the citing paper
“Once-weekly treatment with 1 mg semaglutide reduced the risk of the primary composite outcome by 24% and delayed the progression of kidney dysfunction over a period of 4 years (75).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [75]
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Bikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., Adebayo, O. M., Afarideh, M., Agarwal, S. K., Agudelo-Botero, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30045-3 · Cited by 6,648
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationEmpagliflozin in Patients with Chronic Kidney Disease
The EMPA-KIDNEY Collaborative Group (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2204233 · Cited by 2,754
Cardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Items 1,501–1,600 of 1,871
Gao, C., Menon, G., Chen, Y., Li, Y., Bae, S., Lonze, B. E., Ren‐Fielding, C. J., Chhabra, K. R., Segev, D. L., McAdams‐DeMarco, M., et al. (2026) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2026.09.014
Cardio-renal protection of MRAs in kidney-transplanted diabetic patients
Essawy, B. E., Safa, K., Dalbhi, S. A., & Chandraker, A. K. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108425 · Cited by 2
MASLD and Cardiovascular Risk: Mechanisms and Implications for Clinical Practice
Li, S., Toutoungy, M., Patel, J., Bhavsar‐Burke, I., & VanWagner, L. B. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01380-9 · Cited by 2
“) [66] and reduced CKD progression (FLOW trial) [67 ], supporting its role as a first-line therapy in patients with MASLD and cardiometabolic disease.”
Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide
Oldenburg, L. I. K., Haugaard, S. P., Karlsson, T., Kegel, V., Parwez, M., Wiingaard, C., & Flint, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71096
Escribano‐Serrano, J., Jiménez‐Varo, E., Escribano-Cobalea, M., Casto-Jarillo, C., López-Ceres, A., Campos-Dávila, E., Pozo, A. H., Nieto-Ordoñez, C., Rodríguez-Juliá, M. Á., & Doña, A. M. (2025) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2025.102584 · Cited by 3
Geriatric Pharmacotherapy Case Series: Polypharmacy Leading to Acute Kidney Injury
Lewis, J., Tsu, L. V., & Haider, F. (2025) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2025.315
Waqas, S. A., Ibrahim, M., Ahmed, M., Waqas, M., Aamir, J., Fudim, M., Musani, M. H., Fonarow, G. C., & Greene, S. J. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-01969-6 · Cited by 1
Yukesh, R., Sharma, S., Madhavrao, C., Rangari, G. M., Misra, A. K., Rao, K. S., Vishnu, K., Nayak, B. S., Chagalamari, A., Subalakshmi, R., et al. (2026) · Perspectives in Clinical Research · doi:10.4103/picr.picr_153_26
Gembillo, G., Visconti, L., Tranchida, V., Nardi, C., Calimeri, S., Gambuzza, M. E., Princiotto, M., Chinigò, C., Soraci, L., & Santoro, D. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i4.115058 · Cited by 2
Kushner, R. F., Ryan, D. H., Harder-Lauridsen, N. M., Jeppesen, O. K., Kallenbach, K., Lincoff, A. M., & Lingvay, I. (2025) · Obesity · doi:10.1002/oby.24345
“The Evaluate Renal Function with Semaglutide Once Weekly trial [ 3] reported similar incidences of hip and pelvic fracture events in the semaglutide and placebo arms for female patients (seven vs. five events, respectively) and in patients aged ≥ 75 years (four vs. six events, respectively; data on…”
Chen, Z., Yang, Q., Liu, J. S., Zhao, H., Ying, H., Liu, H., Huang, L., Lin, H. Y., Wang, S., Li, M., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-04888-8
“The FLOW RCT reported the outstanding effect of semaglutide in mitigating risk of clinically important kidney outcomes and death in diabetic individuals [65].”
Revolución metabólica: redefiniendo la endocrinología con nuevas terapias basadas en incretinas
Hernández, A. R., Araujo, J. E. G., Castillo, J. F. D., Martínez, M. E. A., Cohen, N. E. Z., Navarro, A. F. U., Chavez, M. A. N., & Morales, A. L. L. (2025) · Star of Sciences Multidisciplinary Journal · doi:10.63969/tg610p62
Sun, D., Wang, X., Wang, H., Shen, Z., Meng, X., & Zhou, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1933732
Modern pharmacological therapies in nephrology: Progress, promises, and the forgotten role of diet
Borges, N. A., Cardozo, L., Leal, V. D. O., da Silva, L. D. S. F. V., Wesson, D. E., Fouque, D. P., & Mafra, D. (2026) · Clinical Nutrition · doi:10.1016/j.clnu.2026.106781
Lavenburg, L.-M. U., Mosslemi, M., Han, Z., Weltman, M. R., Alghwiri, A. A., Fischer, G. S., Rollman, B. L., Yabes, J. G., & Jhamb, M. (2025) · Diabetes Spectrum · doi:10.2337/ds25-0046
Eyadiel, L., & Modarressi, T. (2025) · Journal of Cardiac Failure - Intersections · doi:10.1016/j.yjcafi.2025.08.015
Cardiometabolic drugs after stroke: time to embrace SGLT2 inhibitors and incretin-based therapies?
Ihle‐Hansen, H., Ihle-Hansen, H., Blauenfeldt, R. A., Dawson, J., Diederichsen, S. Z., & Hagberg, G. (2026) · Frontiers in Stroke · doi:10.3389/fstro.2026.1918465
Haff, N., Horn, D. M., Bhatkhande, G., Sung, M., Colling, C., Wood, W., Robertson, T., Gaposchkin, D. P., Simmons, L. H., Yang, J., et al. (2025) · American Heart Journal · doi:10.1016/j.ahj.2025.02.007 · Cited by 2
Tan, X., Brady, B. L., Xie, L., & Paprocki, Y. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01741-8
“Besides these, semaglutide has also shown benefits in cardiovascular, renal, and metabolic dysfunction-associated steatohepatitis (MASH) outcomes [18–20], which have not been established in other GLP-1 RAs, including liraglutide.”
Are GLP-1 receptor agonists gerotherapeutics or just treatments for obesity?
Peyer, J. G. (2026) · Nature Aging · doi:10.1038/s43587-026-01165-4
Sun, X., Qin, X., & Bi, H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1822990
“Diabetic kidney disease (DKD) is one of the most common and severe microvascular complications of diabetes mellitus and remains a leading cause of end-stage renal disease (ESRD) worldwide (GBD 2021 Risk Factors Collaborators, 2024; Perkovic et al., 2024; Gupta et al., 2023; Agur et al., 2025).”
Neurovascular unit-targeted therapeutic strategies in diabetic retinopathy
Fragiotta, S., Ciancimino, C., & Scuderi, G. (2026) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2026.502655
Real-world outcomes of Finerenone in patients with diabetic kidney disease in Saudi Arabia
Albekery, M. A., Alhomoud, I. S., Alamer, K. A., Alanazi, A. A., Mulhem, A. E. A., Alnaim, A. E., Almulhim, F. M., Al‐Mulhim, A. S., Makhaytah, S. A., Aldawsari, R. A., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0352861
“In addition, glucagon-like peptide-1 (GLP-1) receptor agonists with demonstrated cardiovascular and kidney benefits should be considered as adjunctive therapy, particularly for individuals with established or high risk of developing atherosclerotic cardiovascular disease (ASCVD) [5,13–15].”
Quinaglia, T., Silva, G., Matos‐Souza, J. R., Coelho‐Filho, O. R., Nadruz, W., & Sposito, A. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01368-x
Alhazmi, A. M., Alayoubi, F., Mufti, R. E., & Albulushi, A. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103423
Cardiovascular–Kidney–Metabolic Syndrome and Its Hepatic Dimension: A Narrative Review
Enache, V., Popescu, D.-C., Marcu, B., Diaconu, M., & Nechita, A. C. (2026) · Medicina · doi:10.3390/medicina62091742
“Randomized outcome trials have demonstrated cardiovascular benefit with selected GLP-1 receptor agonists and kidney protection with semaglutide in patients with T2DM and CKD in the Evaluate Renal Function with Semaglutide Once Weekly (FLOW) [111,117].”
Cardiovascular–kidney–metabolic syndrome as a mitochondrial systems disorder
Shen, L., Abel, E. D., Arany, Z. P., Baur, J. A., Pei, L., & Suszták, K. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01127-4 · Cited by 1
Pharmacological treatment for obesity: a scalable solution for South Africa
Conradie-Smit, M., & Lübbe, J. (2026) · South African Journal of Surgery · doi:10.36303/sajs.04658
Factors associated with albuminuria in non-diabetic severe obesity
Toussaint, R., Gentes, E., Pouget, M., Farigon, N., Miolanne, M., Picard, M., Lambert, C., Heng, A.-É., & Boirie, Y. (2026) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2026.103282
Chen, T., & Tsai, S. (2026) · Science Progress · doi:10.1177/00368504261484176
Examining Aging Related Female Adiposity Through the Endocrine Lens
Gülşen, M. R., Pal, L., & Lathief, S. (2026) · Healthy ageing and longevity · doi:10.1007/978-3-032-24097-2_6
If GLP-1s are “longevity drugs,” the evidence bar must change—carefully
Jones, C. H., & Dolsten, M. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104707
Randomized Trials Meet Real-World Evidence in the Era of Combination CKD Therapies
Pecoits-Filho, R., & Bauer, A. C. (2026) · Kidney International Reports · doi:10.1016/j.ekir.2026.106519
Zeyfang, A., Wernecke, J., & Bahrmann, A. (2026) · Die Diabetologie · doi:10.1007/s11428-026-01470-x
Semaglutide: A Tool to Empower Indian Women Against the Twin Challenges of Diabetes and Weight
Lathia, T. B., Beatrice, A., George, B., & Maisnam, I. (2026) · Journal of Diabetology · doi:10.4103/jod.jod_44_26
Fouad, Y. M., AlNaamani, K. M., Alawadi, F., Hassani, A. A., Alkhalidi, N. M. F., Hotayt, B., Abaalkhail, F. A., Rouabhia, S., Abdulla, M., Altarrah, M. Y., et al. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2698115
“In contrast, semaglutide may be a better choice when impaired metabolic health and metabolic risk factors predominate, particularly in patients with comorbid overweight/obesity, type 2 diabetes (T2D), and/or chronic kidney disease, even in individuals with normal BMI and T2D [24,25].”
Glucagon-like peptide-1 (GLP-1) levels are associated with acute kidney injury after cardiac surgery
Szafran, A., Kurt, B., Pracht, J., Zechendorf, E., Breuer, T., Stoppe, C., Marx, G., Tacke, F., Kahles, F., & Mossanen, J. C. (2026) · Scientific Reports · doi:10.1038/s41598-026-48483-6
Tangirala, S., Isaac, S., Gehad, Y., Roquefort, F., Gabrieli, P., Leong, A., Mercader, J. M., Sevilla-González, M. D. R., Baldini, F., Miller, G. W., et al. (2025) · medRxiv · doi:10.1101/2025.09.26.25336579
Semaglutide for Organ Protection
Kharb, S., Bhattacharjee, B., Karuppan, A., V, Khaire, S. S., Routray, P., Ganta, S., Pakhale, K., Pareek, R., Matta, R., Sabharwal, M., et al. (2026) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_27_26
Ayusso, L. L., Girol, A. P., Neto, L. M., Gomes, I., & Burdmann, E. A. (2026) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2025-0349en
“These include SGLT2 inhibitors (dapagliflozin, empagliflozin), mineralocorticoid receptor antagonists (finerenone), and GLP-1 receptor agonists (liraglutide) 57–61 .”
Triozzi, J. L., Chen, H., Mamak, F., Yu, Z., Wilson, O. D., Ikizler, T. A., Ferolito, B. R., Cho, K., Gaziano, J. M., Tao, R., et al. (2025) · medRxiv · doi:10.1101/2025.10.13.25337903
“Their therapeutic applications have expanded to include heart failure and diabetic kidney disease [3,4].”
Goryanin, I., Damms, B., & Goryanin, I. (2026) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70322 · Cited by 1
Merker, L., Ebert, T., Schleicher, E. D., et al. (2025) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2500-1124
“Semaglutide: Recently, a reduction in the combined renal end-point was demonstrated for the GLP-1 receptor agonist sema-glutide in the FLOW study [1].”
Chuang, S., Liu, S.-C., Chien, K., Lin, C. Y., Tsai, M.-C., & Shih, H. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70915
Pendrey, A., Sierra, J. A. R., Lobo, F. A. A., Herrera, E. J. R., Muñoz, Y. M. F., & Sevilla‐Martir, J. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03702-4
“Its effects on inflammation, endothelial function, and atherosclerotic processes contribute to its cardiovascular and renal benefits [15, 16].”
InfluentialMetabolic Polygenic Risk Scores for Prediction of Obesity, Type 2 Diabetes, and Related MorbiditiesPreprint
Kim, M., Chen, Q.-L., Sui, Y., Yang, X., Wang, S.-Q., Weng, L.-C., Cho, S. M. J., Koyama, S., Zhu, X., Yu, K., et al. (2024) · medRxiv · doi:10.1101/2024.11.01.24316620 · Cited by 3
“The GLP-1 receptor agonists are indicated for treating obesity and T2D, yet their indications are expanding as mounting evidence shows their efficacy in reducing cardiovascular diseases, 28 steatohepatitis, 29 chronic kidney disease, 30 and other conditions.”
Nishimura, M., Yonezawa, K., Sawamura, M., Tanaka, T., Yamamoto, Y., Taki, H., Hatao, M., Takeda, M., Hida, K., Koide, J., et al. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109208
European Society of Cardiology Congress 2024 Meeting: Heart Failure Highlights
DONALD, E. M., HAJDUCZOK, A. G., & CAMPBELL, P. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.09.001
Effect of semaglutide on measured versus estimated glomerular filtration rate
Yahya, R., Iversen, E., Sivalingam, S., Christensen, L. W. S., Persson, F., Hansen, T. W., Hornum, M., Rossing, P. R., Curovic, V. R., & Houlind, M. B. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag154
Self-citationZhao, T.-J., & Sun, N. (2026) · World Journal of Diabetes · doi:10.4239/wjd.115342
Incretin analogues as cardiovascular agents: a state-of-the-art review
Garaygordobil, D. A., Rico-Fontalvo, J. E., Hernández-Balbuena, B., Vinay, M., & Gonzalez-Arias, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1898812 · Cited by 1
Xie, F., He, X., Chen, W., Li, J., Lin, S., Bao, Q., Li, W., Cheng, J., Ma, Y., Wu, Z., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1925910 · Cited by 1
GLP-1-basierte Therapie: Aktuelles aus Klinik und Versorgungsalltag
Sonnet, M. (2025) · Info Diabetologie · doi:10.1007/s15034-024-5067-y
Nierenschutz von unterschiedlichen Seiten
Heim, T. M. (2024) · Info Diabetologie · doi:10.1007/s15034-024-5029-4
Rodbard, H. W., Irace, C., Lobo, J., Makrilakis, K., Priyadarshini, P., Sivalingam, S., Tofé, S., & Bhargava, A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71132
Ahmad, W. A., Sagy, Y. W., Arbel, R., Battat, E., Diker, D., Lavie, G., & Reges, O. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107164 · Cited by 1
Clinical Trials in Cardiovascular Medicine
Nogueira, A., Zimerman, A., & Moura, F. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00091-1
Effect of semaglutide add‐on therapy for people living with type 1 diabetes and excess weight
Minsky, N. C., Olshanskiy, D., & Aharon‐Hananel, G. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70389
“5,6 While these benefits remain unproven in T1D, GLP-1RAs represent potentially valuable adjunct therapy for double diabetes.”
Faucon, A., Lando, S., Murata, S., et al. (2025) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2025.08.011
Herz und Diabetes – Was gibt es Neues?
Marx-Schütt, K. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2349-9962
“Die kürzlich veröffentlichte FLOW-Studie (Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes) untersuchte den Einfluss des GLP-1-RA Semaglutid auf das kardiorenale Risiko bei Patienten mit CKD und T2DMin einem randomisierten, placebo-kontrollierten Design [3].”
Impact of renal lipid droplet dynamics on tubular health
Heneberg, P., & Šimčíková, D. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101101
Impact of medication assistance programs in pharmacist managed patients with diabetes
Cherry, M., & Cryder, B. T. (2025) · Discover Medicine · doi:10.1007/s44337-025-00359-w
Semaglutide-a ray of hope for CKD in diabetic patients
Khan, U. (2025) · Journal of the Pakistan Medical Association · doi:10.47391/jpma.21163
GLP-1RA based therapies in the young and old
Rigas, G., Alexander, S., & Haywood, C. J. (2024) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000900
Weingold, R., Filippatos, G. S., Anker, S. D., Wanner, C., Shafi, T., Tangri, N., Pitt, B., BRINKER, M. D., Scott, C. A. B., Roberts, L., et al. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109274
Self-citationChiang, P., Chen, S. C., & Hung, P. (2026) · Research Square · doi:10.21203/rs.3.rs-9573853/v1
Oliveira-Gomes, D. D., de Majo, A. M., Ardila-Delgado, A. D., Inglis, S. S., Mandras, S. A., Loro-Ferrer, J. F., & daSilva‐deAbreu, A. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01395-2
“…modest placebo-adjusted reduction of 4.10 kg at 104 weeks, suggesting complemen - tary metabolic effects that were insufficient to fully account for the observed renal and cardiovascular protection [42]. of GLP-1 and GIP, these agents regulate appetite, glucose metabolism, and energy balance [ 35].”
InfluentialRamadan, A., Aglan, A., Salama, B., Abdalla, M., Fath, A., Frishman, W. H., & Aronow, W. S. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001322
Therapieprinzipien bei Adipositas – was ändert sich in der aktualisierten S3-Leitlinie?
Rohmann, N., Hollstein, T., & Laudes, M. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01900-w · Cited by 1
Lee, C.-M., Kim, J.-Y., Shim, J.-H., & Cho, G.-W. (2026) · Hormone and Metabolic Research · doi:10.1055/a-2928-5204
The therapeutic approach to cardiovascular–kidney–metabolic syndrome
Rangaswami, J., Lo, K. B., & Ndumele, C. E. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01109-6 · Cited by 4
Current trends in semaglutide therapy and strategies to improve its bioavailability
Nayak, S., Dessai, A. D., & Nayak, U. Y. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2688990 · Cited by 3
“Furthermore, emerging evidence suggests that GLP-1 receptor agonists reduce the risk of obesity-linked atrial fibrillation, highlighting broader cardioprotective potential [107].”
Risk factor obesity: treatment standard
Mashayekhi, M., Qing, J., Heidari‐Bateni, G., Mathew, R. O., Liew, A., Kronbichler, A., Lerma, E. V., Abdipour, A., Codorniz, K., Wu, J., et al. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag164
“Albuminuria in the semaglutide group was reduced, with a 40% reduction in urinary albumin-to-creatinine ratio (UACR) at 104 weeks, compared with a 12% reduction with placebo, corresponding to a 32% lower UACR relative to placebo (UACR ratio 0.68; 95% CI, 0.62–0.75) [ 18 ].”
InfluentialUse of semaglutide after acute coronary syndrome: an exploratory retrospective study
Biasin, M., Stratinaki, M., Cordioli, N., Armani, I., Giovanni, S. D., Aletras, G., Betta, D., Callegarin, L., Gambaro, A., & Morani, G. (2026) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001837 · Cited by 1
Marx-Schütt, K., Kintscher, U., Dahm, J. B., Fliser, D., Heine, G. H., Hoyer, J. D., Jung, C., Mahfoud, F., Ott, I., Schlieper, G., et al. (2025) · Die Kardiologie · doi:10.1007/s12181-024-00716-6
Hassan, A. J., Abdulhadi, G. H., & Hasan, E. J. (2026) · Ukrainian Journal of Nephrology and Dialysis · doi:10.31450/ukrjnd.3(91).2026.04
Cardiovascular and Kidney Effects of Glucagon-Like Peptide 1 Receptor Agonists
Sattar, N. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00013-6
Yen, F., Wei, J. C., Sung, C.-Y., Li, P.-Y., Tsai, F. J., Hsu, C., & Hwu, C. (2025) · Pharmaceuticals · doi:10.3390/ph18091368 · Cited by 1
“More recently, the FLOW trial demonstrated that subcutaneous semaglutide significantly reduced the risk of worsening renal function in patients with T2D and chronic kidney disease [24].”
Liu, X., Yuanlin, G., Zhao, B., Teng, H., Liu, W., Xiao, K., & Ma, C. (2026) · Atherosclerosis Plus · doi:10.1016/j.athplu.2026.100570
“It should be emphasised that these car-diorenal indications are established based on dedicated cardiovascular and renal outcome trials [24 – 27], and anti-inflammatory effects, while a potential mechanistic contributor, do not constitute a criterion for clinical selection.”
Teli, B., Sathe, S., Kalra, R., Mahajan, V., Mehta, A., Shinde, R., Kunwar, B., Kahale, P., Sinkar, A., Palimkar, P., et al. (2026) · Cureus · doi:10.7759/cureus.111322
Alawadi, F., Abdelgadir, E., Hassoun, A. A. K., Abusnana, S., Afandi, B. O., Aldahmani, K. M., Alkaabi, J., Bashier, A. M., Bayado, F., Belaila, B. A. B., et al. (2026) · Dubai Diabetes and Endocrinology Journal · doi:10.18502/ddej.v32i1.21067
Novel therapies – IMID Co-morbidities
Lam, T. T., So, H., & Tam, L. (2025) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2025.102089
How Somatic Mutations cause Aging without Causing AgingPreprint
Wolf, A. M. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.6431458
Ghosal, S., & Ghosal, A. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01817-5 · Cited by 1
Pan, S., Weng, C., Sheen, Y., Tsai, S.-F., Lin, J., Chen, J., Lin, C., Huang, S.-P., Chang, C.-J., Lin, H.-J., et al. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.06.023 · Cited by 1
Merker, L., Ebert, T., Schleicher, E. D., Isermann, B., & Guthoff, M. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01273-y
Incretins beyond weight and hyperglycemia management: a consensus statement by AASD
Shaltout, I., Hegazy, M., Meligi, A. A. H. E., Abdelghaffar, S., Wifi, M.-N. A., Saleh, A. A., Hammad, H., Abouzeid, A. A. E. K., Fahmy, E. M., Maghraby, G. G., et al. (2026) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-026-00689-w
Hierarchical composite endpoints for CKD trials
Zoccali, C. (2026) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfag094
Hinton, W., Joy, M., Forbes, A., Whyte, M., Ordóñez-Mena, J. M., Fan, X., Ferreira, F., Meza-Torres, B., Munro, N. M., de Lusignan, S., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70946
“To date, only one reported prospective randomised trial has evaluated the effect of add-on treatment with SGLT2i or GLP-1 Renal Function with Semaglutide Once Weekly (FLOW) trial assessed the effect of semaglutide on kidney outcomes in people with type 2 diabetes and CKD [36].”
Schaefer, G. J. L., & Saritas, T. (2026) · Nephrologie aktuell · doi:10.1055/a-2749-2368
Unoki‐Kubota, H., Nakajima, K., Shimizu, Y., Tamano, S., Kajio, H., Bouchi, R., Yamashita, S., Fukazawa, Y., Seki, N., Matsumoto, M., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-45500-6 · Cited by 1
“Although these medications may cause an acute decline in eGFR, they may improve long-term eGFR trajectories and renal outcomes in contemporary practice, potentially delaying progression to ESKD 25–27 .”
Medenica, S., Prelević, V., Zanković, N., Maggio, V., & Rizzo, M. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2648248 · Cited by 1
Abnormal lipid metabolism in senescent renal tubular cells in diabetic nephropathy
Wan, J., Shen, Y., Yang, X., Chen, J., Chen, K., Chen, K., & Chen, J. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06199-w · Cited by 2
Trajectory of Kidney Function in T1D over Time: A Scoping Review
CO, F., Whitlock, R. H., Katta, A., Aldworth, C., Mares, J. W., Zheng, Z., Ferri, M. B., Askin, N., & Tangri, N. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01899-9
Robert, L., Belalem, I., Vigouroux, C., Dupuis, H., Vantyghem, M., Simonson, M., Nobécourt, E., Mosbah, H., Béliard, S., Jellimann, S., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71126
“…risk of major adverse cardiovascular events (MACE) [15], nephropro-tection with albuminuria reduction and slowing of the progression of renal disease [16] and hepatic benefits through reduction of steatosis and liver inflammation in metabolic-associated ste-atotic liver disease (MASLD) [17].”
Evolving utilization of bariatric surgery since the rise of semaglutide and tirzepatide
Kozato, A., Patel, S. S., Orandi, B. J., Massie, A. M., Mańkowski, M., Fielding, C. R., Segev, D. L., Parikh, M., & Chhabra, K. R. (2026) · Surgical Endoscopy · doi:10.1007/s00464-026-13147-z · Cited by 1
Promoting a turnaround in the management of renal disease in obese patients
Lecube, A., Zamora, J. I., Azriel, S., Barreiro, E., Blay, G., Carretero‐Gómez, J., Ciudin, A., Fernández-García, J. M., Flores, L., de Hollanda, A., et al. (2025) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2025.501358
Nephrologie 2030: digitale Tools für eine effizientere nephrologische Versorgung der Zukunft
Wagenbrenner, M., Beige, J., & Schiffer, M. (2025) · Die Nephrologie · doi:10.1007/s11560-025-00848-0
GLP-1 and GIP/GLP-1 receptor agonists for type 2 diabetes
Morris, D. (2025) · Independent Nurse · doi:10.12968/indn.2025.10.24 · Cited by 1
Pharmacotherapy as Adjunctive Therapy After Bariatric Surgery
Lloyd, S. J., & LaMasters, T. L. (2026) · Springer eBooks · doi:10.1007/978-3-032-24278-5_71
Metadata
- Authors
- Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., & Pratley, R.
- Affiliations
- University of Copenhagen (DK)
- Novo Nordisk A/S, Søborg, Denmark.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-11
- Volume
- 391
- Issue
- 2
- Pages
- 109-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4398781461
- Cited by
- 2,099
- References
- 23
- Citations by year
- 2026: 953 · 2025: 863 · 2024: 281
- FWCI
- 551.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- semaglutide, chronic kidney disease, type 2 diabetes, renal failure, estimated glomerular filtration rate decline, cardiovascular mortality, albuminuria, GLP-1 receptor agonists, renal protection, cardiovascular outcomes, albumin-creatinine ratio, kidney transplantation, dialysis, anemia of chronic kidney disease, diabetic nephropathy, SGLT2 inhibitors
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Glucagon-Like Peptides, Female, Glomerular Filtration Rate, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.